Abstract | INTRODUCTION: AREAS COVERED: Since the initial observation that BRS-3 knockout mice develop obesity, hypertension, impaired glucose metabolism and hyperphagia, there have been numerous studies of the mechanisms involved and the development of selective BRS-3 agonists/antagonists, which have marked effects on body weight, feeding and glucose/ insulin homeostasis. In this review, each of these areas is briefly reviewed. EXPERT OPINION:
BRS-3 plays an important role in glucose/energy homeostasis. The development of potent, selective BRS-3 agonists demonstrates promise as a novel approach to treat obesity/diabetic states. One important question that needs to be addressed is whether BRS-3 agonists need to be centrally acting. This is particularly important in light of recent animal and human studies that report transient cardiovascular side effects with centrally acting oral BRS agonists.
|
Authors | Nieves González, Paola Moreno, Robert T Jensen |
Journal | Expert opinion on therapeutic targets
(Expert Opin Ther Targets)
Vol. 19
Issue 9
Pg. 1153-70
( 2015)
ISSN: 1744-7631 [Electronic] England |
PMID | 26066663
(Publication Type: Journal Article, Research Support, N.I.H., Intramural, Review)
|
Chemical References |
- Insulin
- Receptors, Bombesin
- bombesin receptor subtype 3
- Glucose
|
Topics |
- Animals
- Body Weight
(drug effects)
- Diabetes Mellitus
(drug therapy, physiopathology)
- Drug Design
- Energy Metabolism
(drug effects)
- Glucose
(metabolism)
- Humans
- Insulin
(metabolism)
- Mice
- Mice, Knockout
- Obesity
(drug therapy, physiopathology)
- Receptors, Bombesin
(agonists, antagonists & inhibitors, metabolism)
|